Clinical Trials Sponsored by Hebei Yanda Ludaopei Hospital

Total 35 results

Hebei Yanda Ludaopei Hospital

Completed

LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients

Nutrition Aspect of Cancer | Stem Cell Transplant Complications
Hebei Yanda Ludaopei Hospital

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Min Xiang

Unknown

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

T-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

B-ALL

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

B-cell Non Hodgkin Lymphoma

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.; Beijing Lu Daopei Hospital

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Completed

A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Recruiting

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

CD19+ and CD 22+ B-ALL

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Active, not recruiting

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Unknown

Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

Leukemia
Shanghai Simnova Biotechnology Co.,Ltd.
Hebei Yanda Ludaopei Hospital

Completed

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CMV-TCR-T Cells for CM Virus Infection After HSCT

CMV Infection or Reactivation After Allogenic HSCT

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Terminated

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Refractory and Relapsed B Cell Acute Leukemia

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

B-cell Leukemia

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

EBV-TCR-T Cells for EB Virus Infection After HSCT

EBV Emia and EBV Positive PTLD After Allogenic HSCT

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

B Cell Malignancy

China
Shanghai iCELL Biotechnology Co., Ltd, Shanghai...
Hebei Yanda Ludaopei Hospital

Unknown

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Acute Myeloid Leukemia

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.; Avalon GloboCare Corp.

Completed

CD19-CAR-T in B-cell Malignancies Patients

B-cell Malignancy

China
Hebei Yanda Hospital
Beijing Tiantan Hospital

Unknown

Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas

Glioma

China
Hebei Yanda Hospital
Beijing Tiantan Hospital

Unknown

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Recurrent High-grade Glioma

China
Hebei Yanda Hospital
Beijing Tiantan Hospital

Unknown

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Recurrent High-grade Glioma

China
Beijing Doing Biomedical Co., Ltd.
The First Hospital of Jilin University; Hebei Yanda Ludaopei Hospital

Not yet recruiting

Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia

China
Peking University People's Hospital
Peking University First Hospital; Peking University International Hospital; Hebei...

Recruiting

mNGS Versus Blood Culture in FN

Infections | Hematologic Diseases | Febrile Neutropenia

China
The First Affiliated Hospital of Soochow University
Peking University People's Hospital; Qilu Hospital of Shandong University; Nanfang... and other collaborators

Completed

Prospective Study of Patients With Thrombocytopenia Following HSCT

Hematologic Diseases | Thrombocytopenia

China
Chinese PLA General Hospital
The Second Hospital of Hebei Medical University; Air Force Military Medical... and other collaborators

Completed

First Line Therapy for High Risk Acute GVHD

Stem Cell Transplant Complications | aGVHD

China

Clinical Trials Sponsored by Hebei Yanda Ludaopei Hospital

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations